As illustrated in Fig. 2, Supplementary Fig. 1 and Table 1, compared to CDX2-high tumours, the CDX2-low/absent group showed a decreased OS (CDX2-high 131.2 months vs CDX2-low/absent 100.3 months, P = 0.017), DSS (CDX2-high 158.7 months vs CDX2-low/absent 121.9 months, P = 0.006) and DFS (CDX2-high: 153.9 months vs CDX2-low/absent 114.9 months, P = 0.005) in the overall cohort of 1003 CRCs. This evidence concerns the gene CDX2 and neoplasm.